TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.090
+0.010 (0.93%)
Aug 22, 2025, 4:00 PM - Market closed
TherapeuticsMD Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for TherapeuticsMD.
Price Target: $ (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for TherapeuticsMD.
Recommendation Trends
| Rating | Mar '23 | Apr '23 | May '23 | Jun '23 | Jul '23 | Aug '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $5 | Hold | Reiterates | $5 | +358.72% | Aug 17, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Initiates $5 | Hold | Initiates | $5 | +358.72% | Jan 11, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $1 | Hold | Reiterates | $1 | -8.26% | Jul 13, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $10 | Strong Buy → Hold | Downgrades | $10 | +817.43% | Jun 7, 2022 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $250 → $50 | Buy → Hold | Downgrades | $250 → $50 | +4,487.16% | May 6, 2022 |
Financial Forecast
Revenue This Year
9.28M
from 1.76M
Increased by 427.09%
Revenue Next Year
n/a
from 9.28M
EPS This Year
0.36
from -0.19
EPS Next Year
n/a
from 0.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 |
|---|---|
| High | 9.6M |
| Avg | 9.3M |
| Low | 8.9M |
Revenue Growth
| Revenue Growth | 2025 |
|---|---|
| High | 442.6% |
| Avg | 427.1% |
| Low | 406.4% |
EPS Forecast
| EPS | 2025 |
|---|---|
| High | 0.37 |
| Avg | 0.36 |
| Low | 0.34 |
EPS Growth
| EPS Growth | 2025 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.